Addressing Behavior and Mood in Assisted Living: Organizational Characteristics Related to the Use of Antipsychotic and Psychotropic Medications and Alternative Practices
解决辅助生活中的行为和情绪:与使用抗精神病药物和精神药物以及替代做法相关的组织特征
基本信息
- 批准号:9132160
- 负责人:
- 金额:$ 60.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdmission activityAdverse effectsAdvocacyAffectiveAgeAmericanAntidepressive AgentsAntipsychotic AgentsAssisted Living FacilitiesAttentionAttitudeBedsBehaviorBehavior ControlBehavioralBehavioral SymptomsBenchmarkingBoxingCaringCase MixesCharacteristicsClinicalClinical ServicesCognitiveCountryDataDementiaDistressDoseEducationElderlyFamilyFrequenciesHealthHealth PersonnelHealth ProfessionalHealth ServicesHealthcareHospitalizationImpaired cognitionIndividualInfluentialsInterventionLifeLong-Term CareMedicalMedicineMental HealthModificationMoodsNursing HomesNursing StaffPatternPersonsPharmaceutical PreparationsPhysiciansPoliciesPositioning AttributePrevalenceProtocols documentationPsychiatric DiagnosisPsychotropic DrugsRecording of previous eventsRegulationResearchRiskSamplingSensorySocietiesTrainingUnited States Centers for Medicare and Medicaid ServicesUnited States Food and Drug AdministrationWritingbasedepressive symptomseducation researchenvironmental interventionevidence basehospice environmentinformation organizationmild cognitive impairmentperson centeredpolicy implicationpsychosocialresidenceresponse
项目摘要
DESCRIPTION (provided by applicant): The use of antipsychotic and other psychotropic medications to address behavior and mood among older adults residing in long-term care settings has become a national concern. In 2011, 24% of nursing home residents received antipsychotic medications, despite strong "black box warnings" issued by the federal Food and Drug Administration of their risk of life-threatening adverse effects, as well as the availability f effective non-pharmacological alternatives. In response, in 2012 the Centers for Medicare & Medicaid Services launched a national initiative that to date has reduced antipsychotic use in nursing homes by 17 percent. Emerging evidence suggests grave cause for concern in assisted living residences (ALRs) as well, which provide care for almost 750,000 older adults. Seventy percent of assisted living residents have cognitive impairment, 38% have behavioral symptoms, and 25% have symptoms of depression. New data indicate that 69% of ALRs regularly administer medication to control behavior, and 57% of residents with behavioral symptoms are prescribed a medication - including 42% who have no cognitive impairment and 46% who have only mild cognitive impairment. Further, unlicensed staff administer medications in more than 20% of ALRs, and these same individuals determine when an "as needed" (pro re nata; PRN) medication should be administered. It is no surprise, then, that concern about antipsychotic prescribing in assisted living has become a focus of attention for numerous organizations. Despite notable concern and national attention, there is insufficient information about the actual use of antipsychotic and other psychotropic drugs in ALRs, and virtually no information regarding the settings in which they are most likely to be used and the feasibility of implementing evidence-based alternatives to care. Consequently, it is not possible to develop policies and benchmarks to promote better care as is now occurring in nursing homes. In response, this project, conducted by clinical and health services experts in assisted living research - with close involvement of an advisory board composed of national and state leaders in ALR policy, regulation, practice, education, and advocacy - will obtain and disseminate information to help stakeholders understand the scope of the problem and promote change. Specifically, in a stratified random sample of 280 ALRs across seven states in two regions of the country noted to have the highest and lowest prescribing rates, the proposed study will ascertain (1) the scope and patterns of antipsychotic and other psychotropic medication use; (2) organizational and person-level characteristics related to medication use and potentially inappropriate prescribing; and (3) alternate strategies in use or feasible to address resident distress. It also will (4) disseminate the results to practice, policy, and advocacy stakeholders. t is hypothesized that antipsychotic and other psychotropic medication use, as well as the capacity to implement evidence-based, non-pharmacological practices, will relate to modifiable organizational characteristics that have implications for policy and practice.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sheryl Zimmerman其他文献
Sheryl Zimmerman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sheryl Zimmerman', 18)}}的其他基金
A Pragmatic Crossover Trial to Test the Effectiveness of a Novel Lighting System to Reduce Nighttime Falls in Persons with Alzheimer’s Disease and Related Dementias
一项务实的交叉试验,旨在测试新型照明系统在减少阿尔茨海默病和相关痴呆症患者夜间跌倒方面的有效性
- 批准号:
10649432 - 财政年份:2022
- 资助金额:
$ 60.91万 - 项目类别:
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
评估以人为本的国家培训计划,以加强痴呆症护理人员队伍
- 批准号:
10525110 - 财政年份:2022
- 资助金额:
$ 60.91万 - 项目类别:
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
评估以人为本的国家培训计划,以加强痴呆症护理人员队伍
- 批准号:
10679067 - 财政年份:2022
- 资助金额:
$ 60.91万 - 项目类别:
A Pragmatic Crossover Trial to Test the Effectiveness of a Novel Lighting System to Reduce Nighttime Falls in Persons with Alzheimer’s Disease and Related Dementias
一项务实的交叉试验,旨在测试新型照明系统在减少阿尔茨海默病和相关痴呆症患者夜间跌倒方面的有效性
- 批准号:
10342711 - 财政年份:2022
- 资助金额:
$ 60.91万 - 项目类别:
Holistic Evaluation to Advance Research in Dementia (HEARD): Phased Interdisciplinary Infrastructure Development and Pilot Studies
痴呆症高级研究的整体评估 (HEARD):分阶段跨学科基础设施开发和试点研究
- 批准号:
10818100 - 财政年份:2021
- 资助金额:
$ 60.91万 - 项目类别:
Adapting an Evidence-Based Program that Improves Oral Hygiene and Health for Assisted Living Residents with Dementia
采用循证计划,改善患有痴呆症的辅助生活居民的口腔卫生和健康
- 批准号:
10176330 - 财政年份:2018
- 资助金额:
$ 60.91万 - 项目类别:
Adapting an Evidence-Based Program that Improves Oral Hygiene and Health for Assisted Living Residents with Dementia
采用循证计划,改善患有痴呆症的辅助生活居民的口腔卫生和健康
- 批准号:
9974464 - 财政年份:2018
- 资助金额:
$ 60.91万 - 项目类别:
Adapting an Evidence-Based Program that Improves Oral Hygiene and Health for Assisted Living Residents with Dementia
采用循证计划,改善患有痴呆症的辅助生活居民的口腔卫生和健康
- 批准号:
10470713 - 财政年份:2018
- 资助金额:
$ 60.91万 - 项目类别:
Adapting an Evidence-Based Program that Improves Oral Hygiene and Health for Assisted Living Residents with Dementia
采用循证计划,改善患有痴呆症的辅助生活居民的口腔卫生和健康
- 批准号:
9789809 - 财政年份:2018
- 资助金额:
$ 60.91万 - 项目类别:
Addressing Behavior and Mood in Assisted Living: Organizational Characteristics Related to the Use of Antipsychotic and Psychotropic Medications and Alternative Practices
解决辅助生活中的行为和情绪:与使用抗精神病药物和精神药物以及替代做法相关的组织特征
- 批准号:
8942171 - 财政年份:2015
- 资助金额:
$ 60.91万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 60.91万 - 项目类别:
Research Grant














{{item.name}}会员




